The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The RNA Targeting Small Molecule Drug Discovery Market By The End Of 2030?
The rna targeting small molecule drug discovery market size has seen substantial growth in recent years. It is anticipated to expand from $2.13 billion in 2025 to $2.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.3%. The historical expansion can be linked to the restricted druggability of protein targets, a rising occurrence of genetic disorders, advancements in rna biology research, an increase in academic-industry partnerships, and the initial achievements of rna-based therapeutics.
The rna targeting small molecule drug discovery market size is projected to experience rapid expansion over the coming years. By 2030, this market is anticipated to reach $6.04 billion, exhibiting a compound annual growth rate (CAGR) of 23.5%. Several factors are driving this anticipated growth, including AI-enabled identification of rna targets, a rise in precision medicine investments, the broadening of rna therapeutics pipelines, advancements in rna delivery methods, and supportive regulations for new therapeutic approaches. Key developments foreseen during this period encompass AI-powered rna structure prediction, the broadening of oncology pipelines focused on rna, enhancements in small molecule libraries tailored for rna, greater selectivity and specificity in rna binding, and the incorporation of multi-omics data into rna drug discovery processes.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp
Which Market Drivers Are Supporting The Expansion Of The RNA Targeting Small Molecule Drug Discovery Market?
The rising incidence of cancer, genetic ailments, and viral illnesses is projected to drive expansion within the RNA-targeted small-molecule drug discovery market in the future. Cancer encompasses a range of conditions defined by unchecked cellular proliferation within the organism. Viral infections are those stemming from viruses, which are minute infectious agents capable of replication solely within the cells of living hosts. RNA targeting-based drug discovery offers therapeutic approaches for cancer, genetic disorders, and viral infections, given that these conditions involve genes and dysfunctional genetic material that can be addressed by medications formulated through RNA targeting-based techniques. As an illustration, a report released in February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, estimated 20 million new cancer diagnoses and 9.7 million fatalities worldwide in 2022. The most prevalent type was lung cancer, accounting for 2.5 million new instances (12.4%), succeeded by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). Projections indicate that by 2050, new cancer cases will increase by 77%, exceeding 35 million each year. Consequently, the expanding occurrence of cancer, genetic disorders, and viral infections fuels the expansion of the RNA-targeted small-molecule drug discovery market.
Which Segment Classifications Shape The RNA Targeting Small Molecule Drug Discovery Market?
The rna targeting small molecule drug discovery market covered in this report is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications
Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA
How Are Trends Impacting The RNA Targeting Small Molecule Drug Discovery Market?
Leading companies within the RNA-targeting small-molecule drug discovery market are implementing advanced platforms, such as software-as-a-service models, to secure a competitive advantage. Software-as-a-service (SaaS) is a system for software delivery where a third-party hosts applications and provides them to customers via the internet. As an illustration, in December 2023, Merck & Co. Inc., a US-based science and technology firm, introduced AIDDISON. This platform offers guidance on the optimal synthesis methods for selected medications. This innovative approach has the potential to significantly reduce costs in the drug discovery process and enhance the likelihood of successfully introducing new treatments to patients. By connecting virtual molecular design with practical manufacturing capabilities, the platform boosts the success rate of delivering groundbreaking therapies by uncovering valuable insights from extensive datasets. To expedite the development of medications, this novel artificial intelligence system combines computer-aided drug design, machine learning, and generative AI.
Which Companies Are Expanding Their Footprint In The RNA Targeting Small Molecule Drug Discovery Market?
Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation
Read the full rna targeting small molecule drug discovery market report here:
How Is The RNA Targeting Small Molecule Drug Discovery Market Distributed Across Key Geographic Regions?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored RNA Targeting Small Molecule Drug Discovery Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp
Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company
Rna Targeting Small Molecule Drug Discovery Market Report 2026
Rna Targeting Small Molecules Therapeutics Market Report 2026
Small Molecule Drug Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model